Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence.
about
Improving temporal efficiency of outpatient buprenorphine induction.Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trialAwareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.Consumer attitudes about opioid addiction treatment: a focus group study in New York City.Buprenorphine treatment in an urban community health center: what to expectFactors affecting willingness to provide buprenorphine treatment.Estimating the prevalence of illicit opioid use in New York City using multiple data sources.Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participantsAdoption and implementation of medications in addiction treatment programs.Preliminary survey of office-based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency.The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level AnalysisBridging waitlist delays with interim buprenorphine treatment: initial feasibility.Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural CountiesInterim treatment: Bridging delays to opioid treatment access.Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data.Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physiciansGrowth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11Factors associated with complicated buprenorphine inductionsOptimizing psychosocial support during office-based buprenorphine treatment in primary care: Patients' experiences and preferences.A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphineOffice-based management of opioid dependence with buprenorphine: clinical practices and barriersHome buprenorphine/naloxone induction in primary careTraining physicians to treat substance use disordersDrug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.I heard about it from a friend: assessing interest in buprenorphine treatment.Barriers to primary care physicians prescribing buprenorphine.Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.Enhancing transitions from addiction treatment to primary care.Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact.Perceived Impacts of the Affordable Care Act: Perspectives of Buprenorphine Prescribers.Steps physicians report taking to reduce diversion of buprenorphine.Assessing Differences in the Availability of Opioid Addiction Therapy Options: Rural Versus Urban and American Indian Reservation Versus Nonreservation.Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.Why aren't physicians prescribing more buprenorphine?Buprenorphine physician supply: Relationship with state-level prescription opioid mortality.At the Expense of a Life: Race, Class, and the Meaning of Buprenorphine in Pharmaceuticalized "Care".
P2860
Q30425074-F3FAD77B-D109-48D3-B286-C2CB874F0940Q30432435-8393F7EE-0D94-4CEE-9B65-5002D15B0CBAQ33576948-245FEA57-2748-4044-8845-0CC17350F087Q33576957-EE7687B5-1BB8-43A0-B94F-623CA9860994Q33735289-CB4480A7-D684-4B05-98BD-95CE79801335Q33836333-BEFB64CD-18D9-41C7-804C-25EC1DDF02F8Q34309396-00E63738-6940-4468-984E-85BE147DC557Q34602727-7BAAE6D7-21E6-44B7-B253-26C5619185C7Q34607338-F2176C6B-260E-4F39-B910-550545DF8367Q35345300-00139CAF-449A-43F0-A8AB-9A727D2382FAQ35491054-35D95ECC-6940-4AA0-93E8-49EBFD6565A6Q35577449-297D22BB-5CB2-4AC4-9B62-FD741188EAC0Q35733318-67DB25D3-ED43-4E2B-AC30-EDB2C546E123Q35828982-A0EC3187-31B8-41EA-BD0B-5F4DCDF8F5F3Q36021346-6BD85706-C942-4351-ABB7-EF907A662BDCQ36054084-C2AFA5CF-CDB5-43A6-AEAB-F28AC1E782EEQ36117597-189C4309-532E-44A0-BE45-549F221EF33FQ36367544-2FEA16B5-7F07-4349-9DAE-990DBD7108DFQ36416746-7873822F-D821-4F35-A70B-732A17742EACQ36549928-DE8E16A6-C3D6-42CE-A5F1-7DA52E0FC432Q36585261-26254517-B96B-4A1B-B3BA-A5F323F189BDQ36711972-89855C53-0BAB-4D82-97BE-527ADBA01612Q36753425-20F91D2B-0E35-4ECF-AFA5-22F3B91AB9D2Q36821137-13245712-005D-40D8-814A-5F04F363524EQ36841125-38F0B31E-021B-4F6B-B6B5-C5A15B7BC60EQ37067770-CF30FE90-A99F-4191-AF4C-F1C32A85E0B3Q37273938-01CB6758-AAB2-49AA-AF16-7AC9E51A2A2DQ37393366-8AB24905-A738-40FF-9412-82F4ACAF5466Q37617894-DDD4164C-6B54-4459-99D3-DDA9200A8386Q37628725-2A43064C-4929-472A-B4AF-129AB7D398D2Q37673456-3058D13B-396A-4240-AFCF-02EC90DC5554Q38258422-9251431B-5049-4B78-80E1-C3FA49914CDBQ38734667-A9ED808B-4D6E-4FEF-BD08-50BB7AC841BBQ38906192-9B95FEED-28C0-458A-ADE5-1AF6640091CFQ39429982-9DD4E720-1E5A-475F-B93B-79EB3FE979E1Q39912008-FA80E33C-A693-44CC-B03E-F40E8A9EBA9EQ41210999-DC241633-C7D0-4334-8607-BC6C6F2F3304Q42024652-23F5E3F2-25C1-4736-A1F2-6065F2C09B95Q44344544-4B2B0155-7BA4-4685-A055-EBC5BD62C048Q47182845-23A41651-6270-48FE-B767-603C7FB03AAA
P2860
Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Experiences of a national samp ...... orphine for opioid dependence.
@en
Experiences of a national samp ...... orphine for opioid dependence.
@nl
type
label
Experiences of a national samp ...... orphine for opioid dependence.
@en
Experiences of a national samp ...... orphine for opioid dependence.
@nl
prefLabel
Experiences of a national samp ...... orphine for opioid dependence.
@en
Experiences of a national samp ...... orphine for opioid dependence.
@nl
P2093
P2860
P356
P1476
Experiences of a national samp ...... orphine for opioid dependence.
@en
P2093
Arlene Stanton
Caroline McLeod
Joseph Sonnefeld
Wendy Kissin
P2860
P304
P356
10.1300/J069V25N04_09
P577
2006-01-01T00:00:00Z